Complicated hospitalization due to influenza: results from the Global Hospital Influenza Network for the 2017-2018 season.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
02 Jul 2020
Historique:
received: 03 03 2020
accepted: 17 06 2020
entrez: 4 7 2020
pubmed: 4 7 2020
medline: 22 8 2020
Statut: epublish

Résumé

Since 2011, the Global Influenza Hospital Surveillance Network (GIHSN) has used active surveillance to prospectively collect epidemiological and virological data on patients hospitalized with influenza virus infection. Here, we describe influenza virus strain circulation in the GIHSN participant countries during 2017-2018 season and examine factors associated with complicated hospitalization among patients admitted with laboratory-confirmed influenza illness. The study enrolled patients who were hospitalized in a GIHSN hospital in the previous 48 h with acute respiratory symptoms and who had symptoms consistent with influenza within the 7 days before admission. Enrolled patients were tested by reverse transcription-polymerase chain reaction to confirm influenza virus infection. "Complicated hospitalization" was defined as a need for mechanical ventilation, admission to an intensive care unit, or in-hospital death. In each of four age strata (< 15, 15-< 50, 50-< 65, and ≥ 65 years), factors associated with complicated hospitalization in influenza-positive patients were identified by mixed effects logistic regression and those associated with length of hospital stay using a linear mixed-effects regression model. The study included 12,803 hospitalized patients at 14 coordinating sites in 13 countries, of which 4306 (34%) tested positive for influenza. Influenza viruses B/Yamagata, A/H3N2, and A/H1N1pdm09 strains dominated and cocirculated, although the dominant strains varied between sites. Complicated hospitalization occurred in 10.6% of influenza-positive patients. Factors associated with complicated hospitalization in influenza-positive patients included chronic obstructive pulmonary disease (15-< 50 years and ≥ 65 years), diabetes (15-< 50 years), male sex (50-< 65 years), hospitalization during the last 12 months (50-< 65 years), and current smoking (≥65 years). Chronic obstructive pulmonary disease (50-< 65 years), other chronic conditions (15-< 50 years), influenza A (50-< 65 years), and hospitalization during the last 12 months (< 15 years) were associated with a longer hospital stay. The proportion of patients with complicated influenza did not differ between influenza A and B. Complicated hospitalizations occurred in over 10% of patients hospitalized with influenza virus infection. Factors commonly associated with complicated or longer hospitalization differed by age group but commonly included chronic obstructive pulmonary disease, diabetes, and hospitalization during the last 12 months.

Sections du résumé

BACKGROUND BACKGROUND
Since 2011, the Global Influenza Hospital Surveillance Network (GIHSN) has used active surveillance to prospectively collect epidemiological and virological data on patients hospitalized with influenza virus infection. Here, we describe influenza virus strain circulation in the GIHSN participant countries during 2017-2018 season and examine factors associated with complicated hospitalization among patients admitted with laboratory-confirmed influenza illness.
METHODS METHODS
The study enrolled patients who were hospitalized in a GIHSN hospital in the previous 48 h with acute respiratory symptoms and who had symptoms consistent with influenza within the 7 days before admission. Enrolled patients were tested by reverse transcription-polymerase chain reaction to confirm influenza virus infection. "Complicated hospitalization" was defined as a need for mechanical ventilation, admission to an intensive care unit, or in-hospital death. In each of four age strata (< 15, 15-< 50, 50-< 65, and ≥ 65 years), factors associated with complicated hospitalization in influenza-positive patients were identified by mixed effects logistic regression and those associated with length of hospital stay using a linear mixed-effects regression model.
RESULTS RESULTS
The study included 12,803 hospitalized patients at 14 coordinating sites in 13 countries, of which 4306 (34%) tested positive for influenza. Influenza viruses B/Yamagata, A/H3N2, and A/H1N1pdm09 strains dominated and cocirculated, although the dominant strains varied between sites. Complicated hospitalization occurred in 10.6% of influenza-positive patients. Factors associated with complicated hospitalization in influenza-positive patients included chronic obstructive pulmonary disease (15-< 50 years and ≥ 65 years), diabetes (15-< 50 years), male sex (50-< 65 years), hospitalization during the last 12 months (50-< 65 years), and current smoking (≥65 years). Chronic obstructive pulmonary disease (50-< 65 years), other chronic conditions (15-< 50 years), influenza A (50-< 65 years), and hospitalization during the last 12 months (< 15 years) were associated with a longer hospital stay. The proportion of patients with complicated influenza did not differ between influenza A and B.
CONCLUSIONS CONCLUSIONS
Complicated hospitalizations occurred in over 10% of patients hospitalized with influenza virus infection. Factors commonly associated with complicated or longer hospitalization differed by age group but commonly included chronic obstructive pulmonary disease, diabetes, and hospitalization during the last 12 months.

Identifiants

pubmed: 32615985
doi: 10.1186/s12879-020-05167-4
pii: 10.1186/s12879-020-05167-4
pmc: PMC7330273
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

465

Investigateurs

Sélilah Amour (S)
Coulibaly Anderson N'Gattia (CA)
Victor Baselga Moreno (VB)
Elsa Baumeister (E)
Jalila Ben Khelil (JB)
Daria Danilenko (D)
Javier Diez-Domingo (J)
Anca Cristina Drăgănescu (AC)
Gideon O Emukule (GO)
Zhetpisbayeva Gauhar (Z)
M Lourdes Guerrero (ML)
Ainara Mira-Iglesias (A)
Lidija Kisteneva (L)
Parvaiz A Koul (PA)
Ainagul Kuatbaeva (A)
Victor Alberto Laguna Torres (VAL)
Odile Launay (O)
Nezha Lenzi (N)
Shabir Madhi (S)
Zdenka Mandakova (Z)
Snežana Medić (S)
Mioljub Ristić (M)
Hyder Mir (H)
Aneta Nitsch-Osuch (A)
Nancy Otieno (N)
Daniela Pițigoi (D)
Andrea Pontoriero (A)
Estela Ramirez (E)
Ben Salah (B)
Oana Sandulescu (O)
Natali Serafin (N)
Wei Shan (W)
Anna Sominina (A)
Svetlana Trushakova (S)
Andrzej Zalewski (A)
Tao Zhang (T)

Références

BMC Public Health. 2019 May 2;19(1):487
pubmed: 31046725
Wkly Epidemiol Rec. 2012 Nov 23;87(47):461-76
pubmed: 23210147
Biometrics. 1985 Dec;41(4):991-1000
pubmed: 3830263
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
PLoS One. 2019 Jan 11;14(1):e0210353
pubmed: 30633778
Influenza Other Respir Viruses. 2018 Jan;12(1):22-29
pubmed: 29197154
BMC Public Health. 2016 Aug 22;16 Suppl 1:757
pubmed: 27556802
PLoS One. 2016 May 19;11(5):e0154970
pubmed: 27196667
Clin Infect Dis. 2014 Jul 15;59(2):252-5
pubmed: 24748521
BMC Public Health. 2014 Jun 05;14:564
pubmed: 24903737
Md State Med J. 1965 Feb;14:61-5
pubmed: 14258950
Vaccine. 2018 Apr 12;36(16):2166-2175
pubmed: 29548608
MMWR Morb Mortal Wkly Rep. 2019 Feb 15;68(6):125-134
pubmed: 30763296
Influenza Other Respir Viruses. 2018 Nov;12(6):780-792
pubmed: 29858537
PLoS One. 2014 Jun 19;9(6):e100497
pubmed: 24945510
J Mem Lang. 2008 Nov;59(4):434-446
pubmed: 19884961

Auteurs

Bruno Lina (B)

CIRI, Lyon University, Inserm U 1111, Lyon, France. bruno.lina@chu-lyon.fr.
Hospices Civils de Lyon, Croix-Rousse University Hospital, Infectious Agents Institute (IAI) Laboratory of Virology-National Reference Center for Respiratory Viruses (Including Influenza), Lyon, France. bruno.lina@chu-lyon.fr.
Claude Bernard University (Lyon 1), Lyon, France. bruno.lina@chu-lyon.fr.

Alexandre Georges (A)

OpenHealth, Paris, France.

Elena Burtseva (E)

FSBI "N.F. Gamaleya NRCEM", Moscow, Russian Federation.

Marta C Nunes (MC)

Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases Unit, University of the Witwatersrand, Johannesburg, South Africa.

Melissa K Andrew (MK)

Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Canada.

Shelly A McNeil (SA)

Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Canada.

Guillermo M Ruiz-Palacios (GM)

National Institutes of Health, Mexico City, Mexico.

Luzhao Feng (L)

Division of Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, China.

Jan Kyncl (J)

National Institute of Public Health, Prague, Czech Republic.

Philippe Vanhems (P)

Groupement Hospitalier Edouard Herriot, Unité d'Hygiène, Epidémiologie et Prévention, Hospices Civils de Lyon, Lyon, France.
Emerging Pathogens Laboratory - Epidemiology and International Health, Fondation Mérieux, Centre International de Recherche en Infectiologie (CIRI), Lyon, France.
Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), CIC, 1417, Paris, France.

Justin R Ortiz (JR)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.

John Paget (J)

Netherlands Institute for Health Services Research (NIVEL), Utrecht, The Netherlands.

Robert C Reiner (RC)

Institute of Health Metrics and Evaluation, Department of Health Metrics Sciences, University of Washington, Seattle, WA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH